Why the study?
Atherosclerotic disease is driven by multiple factors like hypertension, dyslipidemia, and diabetes rather than a single pathology, prompting the creation of a metabolic syndrome mouse model to elucidate its mechanisms.
A novel metabolic syndrome mouse model combining ApoE knockout with a high-fat diet, angiotensin II, and streptozotocin successfully replicates severe atherosclerosis driven by oxidative stress and inflammation.
Should not change clinical practice; extends preclinical models for metabolic syndrome-driven atherosclerosis.
Background Atherosclerotic disease is influenced by multiple factors including hypertension, dyslipidemia, and diabetes and it is rarely due to a single pathology in clinical conditions. In this study, we created a mouse model of metabolic syndrome and aimed to elucidate the mechanism of atherosclerosis in metabolic syndrome. Methods Twelve-week-old male apolipoprotein E knockout mice were fed a high-fat diet to produce dyslipidemia, administered angiotensin II continuously to develop hypertension, and infused with streptozotocin intraperitoneally at 18 weeks to produce diabetes mellitus for metabolic syndrome (METS) mice. Control (CTL), high-fat diet alone, angiotensin II alone, and streptozotocin alone mice were also produced and the results in the various groups were compared. Results The METS group showed increased body weight, blood pressure, and serum total cholesterol. The METS group exhibited a significantly higher rate of atherosclerosis formation than the CTL group (METS; 25.7±11.6 %, CTL: 3.3±1.5 %, p<0.001). The expressions of nicotinamide adenine dinucleotide phosphate oxidase 2, nuclear factor-kappa B1, and matrix metalloproteinase-2 in the METS group were significantly higher than those in the CTL group by reverse transcription-polymerase chain reaction analysis. Conclusions The METS model mouse showed severe atherosclerosis caused by oxidative stress, inflammation, and atherosclerotic plaque formation. This model is expected to be useful as a model that more closely resembles the pathophysiology of clinical atherosclerosis. Perspective What Is New? This study introduces a novel metabolic syndrome mouse model that closely resembles human atherosclerosis by integrating hypertension, dyslipidemia, and diabetes into an apolipoprotein E knockout mouse. What Are the Clinical Implications? The metabolic syndrome mouse model demonstrates severe atherosclerosis driven by oxidative stress and inflammation, making it a valuable tool for testing therapeutic strategies targeting metabolic syndrome-related cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Tsudome et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: